Cubist Systematic Strategies, LLC Annovis Bio, Inc. Transaction History
Cubist Systematic Strategies, LLC
- $15.1 Billion
- Q4 2024
A detailed history of Cubist Systematic Strategies, LLC transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 51,347 shares of ANVS stock, worth $114,503. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,347Holding current value
$114,503% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding ANVS
# of Institutions
48Shares Held
1.56MCall Options Held
348KPut Options Held
535K-
Vanguard Group Inc Valley Forge, PA466KShares$1.04 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il215KShares$479,9110.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$224,5810.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.6KShares$222,0270.0% of portfolio
-
Merit Financial Group, LLC98.5KShares$219,6900.01% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $18.2M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...